Shares of our penny stock alert from Jun 25, OncoSec Medical Inc. (OTCQB: ONCS) are breaking past 0.30 on what could be a record volume trading session. ONCS stock price has risen as high as 0.298 so far in today’s trading session and has gained 65% now since our initial alert at 0.18. The developers of the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors announced today approval of a Phase II clinical trial evaluating OncoSec’s OMS ElectroImmunotherapy for the treatment of cutaneous T-cell lymphoma.
Looking for Hot Penny Stocks? Click here and get Alerts on the Best Penny Stocks FREE.
ONCS Stock Chart
A total of up to 27 patients with cutaneous T-cell lymphoma will be enrolled in this Phase II, single-arm, open-label multi-center study. The trial’s primary endpoint is to assess local and distant response rate following treatment of cutaneous T-cell lymphoma lesions (mycosis fungoides or Sezary patients) with a DNA-based cytokine coded for the immune stimulating agent interleukin-12 (DNA IL-12) and electroporation.
One treatment cycle will consist of three treatments applied to up to four lesions on days one, five and eight with a maximum dose of 3.0 mg DNA IL-12 per treatment cycle. Patients with stable disease or better at three months will be eligible to receive a second treatment cycle.
Additional treatment cycles at six, nine and 12 months can be applied if there is no evidence of disease progression or intolerability of the treatment, with a maximum of four cycles. Treatment response at untreated sites will be evaluated according to the standard modified SWAT definition. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety. The first patient has been enrolled and successfully completed their first treatment cycle.
About ONCS Stock
OncoSec Medical Inc. is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumors and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution for less invasive and less expensive therapies that are able to minimize the detrimental effects resulting from traditional cancer treatments.
OncoSec’s core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine or a chemotherapeutic agent. Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers.
Bottom Line: The penny stock of OncoSec is bullish, to say the least, and still worth a buy according to stockcharts.com. All short and medium term indicators have ONCS stock ranked as a buy as the penny stock tests levels not seen since March of this year. Could ONCS stock reach $1.99 high it had in 2011?
Here is your opportunity to subscribe to the Most Exclusive Penny Stock newsletter.
Sign up with your email address now & get ready to make BIG PROFITS on Good Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)
And Remember to Always:Share